(Q51547813)

6 April 2018

title

Vasohibin-1 as a potential predictor of aggressive behavior of ductal carcinoma in situ of the breast. (English)

1 reference

6 April 2018

1 reference

7

Yasufumi Sato

1 reference

6 April 2018

Hironobu Sasano

2

object named as

Hironobu Sasano

1 reference

6 April 2018

author name string

Kentaro Tamaki

1

1 reference

6 April 2018

Yohei Maruo

3

1 reference

6 April 2018

Yayoi Takahashi

4

1 reference

6 April 2018

Minoru Miyashita

5

1 reference

6 April 2018

Takuya Moriya

6

1 reference

6 April 2018

Hisashi Hirakawa

8

1 reference

6 April 2018

Nobumitsu Tamaki

9

1 reference

6 April 2018

Mika Watanabe

10

1 reference

6 April 2018

Takanori Ishida

11

1 reference

6 April 2018

Noriaki Ohuchi

12

1 reference

6 April 2018

publication date

1 April 2010

1 reference

6 April 2018

published in

Cancer Science

1 reference

6 April 2018

volume

101

1 reference

6 April 2018

issue

4

1 reference

6 April 2018

page(s)

1051-1058

1 reference

6 April 2018

Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2009.01483.X

The vasohibin family: a negative regulatory system of angiogenesis genetically programmed in endothelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2009.01483.X

Angiogenesis in cancer, vascular, rheumatoid and other disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2009.01483.X

Update on endogenous inhibitors of angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2009.01483.X

Gene regulation of a novel angiogenesis inhibitor, vasohibin, in endothelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2009.01483.X

Vasohibin: the feedback on a new inhibitor of angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2009.01483.X

Multiple processing forms and their biological activities of a novel angiogenesis inhibitor vasohibin

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2009.01483.X

Vascular endothelial growth factor: basic science and clinical progress

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2009.01483.X

Expression of vasohibin as a novel endothelium-derived angiogenesis inhibitor in endometrial cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2009.01483.X

Vasohibin-1 in human breast carcinoma: a potential negative feedback regulator of angiogenesis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2009.01483.X

Characteristics associated with recurrence among women with ductal carcinoma in situ treated by lumpectomy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2009.01483.X

Ductal carcinoma in situ of the breast (DCIS) with heterogeneity of nuclear grade: prognostic effects of quantitative nuclear assessment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2009.01483.X

Tumor-associated endothelial cells with cytogenetic abnormalities.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2009.01483.X

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2009.01483.X

MDM2: a novel mineralocorticoid-responsive gene involved in aldosterone-induced human vascular structural remodeling.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2009.01483.X

Tumor angiogenesis and metastasis--correlation in invasive breast carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2009.01483.X

Tumor angiogenesis: a new significant and independent prognostic indicator in early-stage breast carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2009.01483.X

Cyclooxygenase-2 expression and angiogenesis in squamous cell carcinoma of the skin and its precursors: a paired immunohistochemical study of 35 cases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2009.01483.X

The immunohistochemical assessment of hypoxia, vascularity and proliferation in bladder carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2009.01483.X

Intraductal carcinoma of the breast: Follow-up after biopsy only

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2009.01483.X

Upregulation of focal adhesion kinase (FAK) expression in ductal carcinoma in situ (DCIS) is an early event in breast tumorigenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2009.01483.X

The extent of proliferative and apoptotic activity in intraductal and invasive ductal breast carcinomas detected by Ki-67 labeling and terminal deoxynucleotidyl transferase-mediated digoxigenin-11-dUTP nick end labeling.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2009.01483.X

Expression patterns of angiogenic and lymphangiogenic factors in ductal breast carcinoma in situ

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2009.01483.X

Distinct angiogenic patterns are associated with high-grade in situ ductal carcinomas of the breast.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2009.01483.X

Angiogenesis is associated with the onset of hyperplasia in human ductal breast disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2009.01483.X

The assessment of angiogenesis and fibroblastic stromagenesis in hyperplastic and pre-invasive breast lesions.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2009.01483.X

Bevacizumab in the treatment of breast cancer: rationale and current data

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2009.01483.X

Breast tumour angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2009.01483.X

Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2009.01483.X

Antiangiogenic and antitumor effects of bevacizumab in patients with inflammatory and locally advanced breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2009.01483.X

10.1111/J.1349-7006.2009.01483.X

21 January 2018

Identifiers

DOI

1 reference

6 April 2018

PubMed ID

20704578

1 reference

6 April 2018